*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| | |
|---|---|
| **Name of entity** | Botanix Pharmaceuticals Ltd |
| **ABN** | 70 009 109 755 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | Vincent Ippolito |
| **Date of last notice** | 24 April 2026 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct and Indirect |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust |
| **Date of change** | 22 September 2026 |
| **No. of securities held prior to change** | **Vincent Peter Ippolito**<br>16,000,000 Performance Rights (expiring 2 December 2029)<br><br>**Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust**<br>16,668,311 Fully Paid Ordinary Shares<br><br>1,666,667 unquoted options exercisable at $0.06, expiring on 31 January 2027 |
| **Class** | Performance Rights (expiring 2 December 2029)<br>Fully Paid Ordinary Shares |
| **Number acquired** | 4,000,000 Fully paid ordinary shares |
| **Number disposed** | 4,000,000 Performance Rights (expiring 2 December 2029) |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Nil – conversion of $0 exercise price performance rights. |

| | |
|---|---|
| **No. of securities held after the change** | **Vincent Peter Ippolito**<br>4,000,000 Fully Paid Ordinary Shares<br><br>12,000,000 Performance Rights (expiring 2 December 2029)<br><br>**Vincent Peter Ippolito and Karen Ann Ippolito <The Ippolito Trust> - trustee and beneficiary of the trust**<br>16,668,311 Fully Paid Ordinary Shares<br><br>1,666,667 unquoted options exercisable at $0.06, expiring on 31 January 2027 |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Exercise of performance rights issued under the employee incentive plan. |

## Part 2 – Change of director's interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | N/A |
| **Nature of interest** | N/A |
| **Name of registered holder**<br>**(if issued securities)** | N/A |
| **Date of change** | N/A |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | N/A |
| **Interest acquired** | N/A |
| **Interest disposed** | N/A |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | N/A |
| **Interest after change** | N/A |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | N/A |
| **If prior written clearance was provided, on what date was this provided?** | N/A |